Stem definition | Drug id | CAS RN |
---|---|---|
antibiotics, protein-synthesis inhibitors, tetracycline derivatives | 802 | 127-33-3 |
Dose | Unit | Route |
---|---|---|
0.60 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 1.50 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 47 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 32.27 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 66 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 1.30 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 1.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.59 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 12 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 14, 1960 | FDA | LEDERLE |
None
None
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Paraneoplastic rash | 49.83 | 42.29 | 6 | 460 | 88 | 79743834 |
Diabetes insipidus | 48.03 | 42.29 | 10 | 456 | 5227 | 79738695 |
Hyponatraemia | 43.60 | 42.29 | 21 | 445 | 177827 | 79566095 |
None
Source | Code | Description |
---|---|---|
ATC | D06AA01 | DERMATOLOGICALS ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE ANTIBIOTICS FOR TOPICAL USE Tetracycline and derivatives |
ATC | J01AA01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE TETRACYCLINES Tetracyclines |
FDA CS | M0021223 | Tetracyclines |
FDA EPC | N0000175505 | Tetracycline-class Antimicrobial |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
CHEBI has role | CHEBI:176497 | geroprotectors |
CHEBI has role | CHEBI:194423 | aquaretic agent |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Trachoma | indication | 2576002 | DOID:11265 |
Actinomycotic infection | indication | 11817007 | DOID:8478 |
Gonorrhea | indication | 15628003 | DOID:7551 |
Haemophilus Influenzae Acute Otitis Media | indication | 19021002 | |
Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
Gingivostomatitis | indication | 20607006 | |
Acute gonococcal cervicitis | indication | 20943002 | DOID:10615 |
Granuloma inguinale | indication | 28867007 | DOID:9113 |
Acute gonococcal urethritis | indication | 29864006 | |
Bronchitis | indication | 32398004 | DOID:6132 |
Sinusitis | indication | 36971009 | |
Gonorrhea of rectum | indication | 42746002 | |
Klebsiella cystitis | indication | 60867007 | |
Acute gonococcal endometritis | indication | 65295003 | DOID:7527 |
Urinary tract infectious disease | indication | 68566005 | |
Yaws | indication | 70647001 | DOID:10371 |
Gonorrhea of pharynx | indication | 74372003 | |
Rickettsialpox | indication | 75096007 | DOID:11103 |
Ornithosis | indication | 75116005 | DOID:11262 |
Acute bacterial sinusitis | indication | 75498004 | |
Brucellosis | indication | 75702008 | DOID:11077 |
Syphilis | indication | 76272004 | |
Rocky Mountain spotted fever | indication | 186772009 | |
Q fever | indication | 186788009 | DOID:11100 |
Lymphogranuloma venereum | indication | 186946009 | DOID:13819 |
Pneumonia | indication | 233604007 | DOID:552 |
Inclusion conjunctivitis | indication | 266109000 | |
Chancroid | indication | 266143009 | DOID:13778 |
Infective otitis media | indication | 312218008 | |
Pharyngitis | indication | 405737000 | DOID:2275 |
Infection due to Staphylococcus aureus | indication | 406602003 | |
Anthrax | indication | 409498004 | DOID:7427 |
Relapsing fever | indication | 420079008 | DOID:13034 |
Typhus Infections | indication | ||
Haemophilus Influenzae Pharyngitis | indication | ||
Tularemia | off-label use | 19265001 | |
Enterocolitis | off-label use | 43752006 | |
Pneumonia due to Mycoplasma pneumoniae | off-label use | 46970008 | |
Syndrome of inappropriate vasopressin secretion | off-label use | 55004003 | DOID:3401 |
Plague | off-label use | 58750007 | DOID:3482 |
Cholangitis | off-label use | 82403002 | DOID:9446 |
Chlamydial infection | off-label use | 105629000 | |
Infectious disease of abdomen | off-label use | 128070006 | |
Ocular rosacea | off-label use | 200933006 | |
Diabetes insipidus | contraindication | 15771004 | DOID:9409 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Pregnancy, function | contraindication | 289908002 | |
Pseudomembranous enterocolitis | contraindication | 397683000 | |
Breastfeeding (mother) | contraindication | 413712001 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 3.25 | acidic |
pKa2 | 7.09 | acidic |
pKa3 | 7.7 | acidic |
pKa4 | 11.73 | acidic |
pKa5 | 12.35 | acidic |
pKa6 | 13.08 | acidic |
pKa7 | 9.5 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Estrogen receptor beta | Nuclear hormone receptor | IC50 | 7.21 | CHEMBL | |||||
30S ribosomal protein S4 | Ribosomal protein | WOMBAT-PK | |||||||
30S ribosomal protein S9 | Ribosomal protein | WOMBAT-PK |
ID | Source |
---|---|
4019707 | VUID |
N0000147799 | NUI |
D03680 | KEGG_DRUG |
64-73-3 | SECONDARY_CAS_RN |
3154 | RXNORM |
4017921 | VANDF |
4019707 | VANDF |
C0011276 | UMLSCUI |
CHEBI:4392 | CHEBI |
CHEMBL1591 | ChEMBL_ID |
CHEMBL1200474 | ChEMBL_ID |
D003707 | MESH_DESCRIPTOR_UI |
DB00618 | DRUGBANK_ID |
10905 | IUPHAR_LIGAND_ID |
917 | INN_ID |
5R5W9ICI6O | UNII |
54680690 | PUBCHEM_CID |
4543 | MMSL |
50744 | MMSL |
d01068 | MMSL |
002745 | NDDF |
004862 | NDDF |
10324005 | SNOMEDCT_US |
372779007 | SNOMEDCT_US |
5737008 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-625 | TABLET, FILM COATED | 150 mg | ORAL | ANDA | 25 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-626 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 25 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24658-710 | TABLET, FILM COATED | 150 mg | ORAL | ANDA | 21 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24658-711 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 21 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42806-143 | TABLET, FILM COATED | 150 mg | ORAL | ANDA | 21 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42806-144 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 21 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53746-554 | TABLET | 150 mg | ORAL | ANDA | 13 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53746-554 | TABLET | 150 mg | ORAL | ANDA | 13 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53746-555 | TABLET | 300 mg | ORAL | ANDA | 13 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53746-555 | TABLET | 300 mg | ORAL | ANDA | 13 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60429-649 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 21 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60429-663 | TABLET, FILM COATED | 150 mg | ORAL | ANDA | 21 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60687-691 | TABLET | 150 mg | ORAL | ANDA | 22 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60687-691 | TABLET | 150 mg | ORAL | ANDA | 22 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60687-705 | TABLET | 300 mg | ORAL | ANDA | 22 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60687-705 | TABLET | 300 mg | ORAL | ANDA | 22 sections |
demeclocycline hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61748-113 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 27 sections |
demeclocycline hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61748-115 | TABLET, FILM COATED | 150 mg | ORAL | ANDA | 27 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62584-159 | TABLET | 150 mg | ORAL | ANDA | 24 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62584-159 | TABLET | 150 mg | ORAL | ANDA | 24 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62584-159 | TABLET | 150 mg | ORAL | ANDA | 24 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62584-163 | TABLET | 300 mg | ORAL | ANDA | 24 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62584-163 | TABLET | 300 mg | ORAL | ANDA | 24 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62584-163 | TABLET | 300 mg | ORAL | ANDA | 24 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-554 | TABLET | 150 mg | ORAL | ANDA | 13 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-554 | TABLET | 150 mg | ORAL | ANDA | 13 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-555 | TABLET | 300 mg | ORAL | ANDA | 13 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-555 | TABLET | 300 mg | ORAL | ANDA | 13 sections |
Demeclocycline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-0155 | TABLET | 150 mg | ORAL | ANDA | 12 sections |